Diagenode

>>>   Click for Diagenode’s approach to COVID-19

News

PRESS RELEASE
November 8, 2013

Diagenode Launches Extensively Validated Epigenetic Antibodies for Broad Research Use

Industry’s most highly validated antibodies as used by the BLUEPRINT Epigenome Consortium researchers are now broadly available for epigenetics researchers worldwide.

Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched its “Premium” line of antibodies for epigenetics applications such as chromatin immunoprecipitation (ChIP) and DNA methylation. These antibodies have been extensively validated for high sensitivity and specificity through a multi-step process including assessment through ELISA, dot blot, peptide arrays, Western blot, IF, CHIP-qPCR, and ChIP-seq. They were initially developed in a collaborative effort for the well-known BLUEPRINT Epigenome consortium and now have been released for widespread research use.

 

Read more

Events

  • ChIP workshop
    Diagenode
    Sep 21-Sep 22, 2021
  • DNA methylation workshop: Master MeDIP assay
    Diagenode
    Sep 30, 2021
  • DNA methylation workshop: Become an expert at RRBS
    Diagenode
    Oct 1-Oct 31, 2021
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics